Want to see QNCX full AI Analyst Report?
QNCX Stock Chart & Stats
$30.93
-$0.43(-2.32%)
At close: 4:00 PM EDT
$30.93
-$0.43(-2.32%)
Day’s Range― - ―
52-Week Range$15.10 - $909.80
Previous CloseN/A
Volume15.25K
Average Volume (3M)22.10K
Market Cap
$32.27M
Enterprise Value$139.39M
Total Cash (Recent Filing)$115.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Nov 18, 2026EPS Estimate
-1.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-68.91
Shares Outstanding1,017,063
10 Day Avg. Volume26,739
30 Day Avg. Volume22,104
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-4.70
Price to Sales (P/S)0.00
P/FCF Ratio-4.02
Enterprise Value/Market Cap4.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.87K
Enterprise Value/Ebitda-1.93
Forecast
1Y Price Target
$75.63Price Target Upside144.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-9.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe latest trailing balance-sheet position shows no debt and positive equity, reducing interest burden and near-term creditor pressure. This gives Quince greater flexibility to direct available capital toward clinical development and other operating priorities while limiting leverage-related financial risk.
Focused Pulmonary PipelineThe post-merger focus on LAM-001 creates a more concentrated development strategy around an investigational inhaled rapamycin formulation and multiple Phase 2 pulmonary indications. A focused pipeline can improve resource allocation and provide several potential clinical milestones over the next several quarters.
Recent Financing CapacityThe completed financing materially expands the resources available to advance clinical programs and fund operations compared with relying solely on routine equity raises. Potential additional warrant proceeds could further extend development capacity if the related instruments are exercised.
Bears Say
Pre-revenue Losses And Cash BurnQuince has no commercial revenue base to offset development expenses, while losses have widened and free cash flow remains substantially negative. Continued cash consumption increases dependence on external financing and makes future financial performance highly dependent on clinical and funding outcomes.
Nasdaq Equity Compliance PressureThe Nasdaq notice indicates that reported equity fell materially below the applicable minimum, creating an ongoing listing-compliance burden. Even with a proposed Capital Market move, restoring compliance requires execution and approvals, adding governance and financing uncertainty over the coming months.
Substantial Potential DilutionThe approved equity structure can significantly increase the common share count and alter existing investors’ ownership and voting positions. Although it supports funding flexibility, the scale of potential issuance may dilute current holders and complicate capital allocation and control dynamics.
Quince Therapeutics News
QNCX FAQ
What was Quince Therapeutics’s price range in the past 12 months?
Quince Therapeutics lowest stock price was $15.10 and its highest was $909.80 in the past 12 months.
What is Quince Therapeutics’s market cap?
Quince Therapeutics’s market cap is $32.27M.
When is Quince Therapeutics’s upcoming earnings report date?
Quince Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 37 days.
How were Quince Therapeutics’s earnings last quarter?
Quince Therapeutics released its earnings results on Aug 14, 2026. The company reported -$12.31 earnings per share for the quarter, beating the consensus estimate of -$28.02 by $15.71.
Is Quince Therapeutics overvalued?
According to Wall Street analysts Quince Therapeutics’s price is currently Undervalued.
Does Quince Therapeutics pay dividends?
Quince Therapeutics does not currently pay dividends.
What is Quince Therapeutics’s EPS estimate?
Quince Therapeutics’s EPS estimate is -1.39.
How many shares outstanding does Quince Therapeutics have?
Quince Therapeutics has 1,017,063 shares outstanding.
What happened to Quince Therapeutics’s price movement after its last earnings report?
Quince Therapeutics reported an EPS of -$12.31 in its last earnings report, beating expectations of -$28.02. Following the earnings report the stock price went up 5.029%.
Which hedge fund is a major shareholder of Quince Therapeutics?
Currently, no hedge funds are holding shares in QNCX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quince Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$75.63 (144.50% Upside)
$75.63 (144.50% Upside)
Blogger Sentiment
Bullish
QNCX Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 25.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.22%
12-Months-Change
Fundamentals
Return on Equity
-413.28%
Trailing 12-Months
Asset Growth
5.79%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Quince Therapeutics
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
QNCX Stock 12 Month Forecast
Average Price Target
$75.63
▲(144.50% Upside)
Technical Analysis
Ownership Overview
50.74% Insiders
0.02% Mutual Funds
0.39% Other Institutional Investors
48.57% Public Companies and
Individual Investors